Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Neoplasms 1 Diabetes Mellitus, Type 2 1

Interventions

Gemcitabine 57 130-nm albumin-bound paclitaxel 35 Specimen Handling 26 Magnetic Resonance Spectroscopy 21 Albumin-Bound Paclitaxel 21 Fluorouracil 20 Leucovorin 19 Irinotecan 19 Oxaliplatin 17 Biopsy 17 Taxes 16 pembrolizumab 13 Cyclophosphamide 11 Cisplatin 11 fludarabine 10 Cetuximab 9 Capecitabine 8 Nivolumab 7 Carboplatin 7 irinotecan sucrosofate 6 durvalumab 6 dehydroftorafur 6 Radiosurgery 6 Pemetrexed 6 olaparib 5 Ipilimumab 5 Erlotinib Hydrochloride 5 trastuzumab deruxtecan 4 aldesleukin 4 Radiotherapy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Sulfonylurea Compounds × 90 days × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡